Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc.

4Q23 results included charges related to the Daiichi Sankyo collaboration .

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

(AP Photo/Rod Lamkey, Jr.) WASHINGTON (AP) — The man who hopes to be President Donald Trump’s health secretary repeatedly asked to see “data” or “science” showing vaccines are safe – but when an ...